Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 22 04:00PM ET
0.3951
Dollar change
-0.0020
Percentage change
-0.50
%
Index- P/E- EPS (ttm)-1.86 Insider Own10.03% Shs Outstand207.51M Perf Week-8.12%
Market Cap81.99M Forward P/E- EPS next Y-0.18 Insider Trans0.00% Shs Float186.71M Perf Month-12.30%
Income-328.05M PEG- EPS next Q-0.15 Inst Own49.04% Short Float8.31% Perf Quarter-22.76%
Sales18.76M P/S4.37 EPS this Y64.58% Inst Trans6.83% Short Ratio6.73 Perf Half Y-8.56%
Book/sh0.28 P/B1.42 EPS next Y65.94% ROA-115.20% Short Interest15.51M Perf Year-72.27%
Cash/sh0.27 P/C1.48 EPS next 5Y- ROE-167.24% 52W Range0.29 - 1.53 Perf YTD-27.28%
Dividend Est.- P/FCF- EPS past 5Y-15.96% ROI-374.86% 52W High-74.15% Beta1.23
Dividend TTM- Quick Ratio1.71 Sales past 5Y17.84% Gross Margin-2.77% 52W Low35.73% ATR (14)0.05
Dividend Ex-Date- Current Ratio1.71 EPS Y/Y TTM-126.97% Oper. Margin-1259.72% RSI (14)43.90 Volatility14.01% 13.09%
Employees405 Debt/Eq0.54 Sales Y/Y TTM-92.22% Profit Margin-1749.06% Recom2.00 Target Price3.80
Option/ShortYes / Yes LT Debt/Eq0.54 EPS Q/Q-317.93% Payout- Rel Volume0.35 Prev Close0.40
Sales Surprise-92.43% EPS Surprise-26.29% Sales Q/Q-99.70% EarningsMay 09 AMC Avg Volume2.30M Price0.40
SMA20-0.26% SMA50-20.55% SMA200-29.51% Trades Volume811,305 Change-0.50%
Date Action Analyst Rating Change Price Target Change
Nov-03-23Downgrade RBC Capital Mkts Outperform → Sector Perform $6 → $2
Apr-28-23Downgrade BofA Securities Neutral → Underperform $5 → $1.50
Feb-27-23Upgrade Wedbush Neutral → Outperform $16
Jan-06-23Downgrade BofA Securities Buy → Neutral $8 → $5
Jun-13-22Resumed Wedbush Neutral $5
May-04-21Initiated RBC Capital Mkts Outperform $22
Jan-07-21Resumed Guggenheim Neutral $16
Jan-06-21Initiated Stifel Hold $16
Dec-16-20Resumed H.C. Wainwright Buy $25
Sep-08-20Initiated BofA Securities Buy $20
May-12-24 08:28AM
May-10-24 03:58PM
May-09-24 08:58PM
05:25PM
04:23PM
04:01PM Loading…
04:01PM
10:46AM
08:05AM
May-02-24 04:15PM
Apr-22-24 04:35PM
Mar-22-24 08:05AM
Mar-14-24 07:23AM
Mar-13-24 08:21AM
08:05AM
08:01AM
06:30PM Loading…
Mar-12-24 06:30PM
Feb-12-24 08:05AM
Feb-05-24 06:01PM
Nov-03-23 05:03PM
Nov-02-23 08:15AM
Nov-01-23 07:05PM
04:13PM
04:01PM
Oct-26-23 10:02AM
Oct-25-23 04:15PM
Oct-24-23 02:01AM
Sep-20-23 04:15PM
Aug-25-23 01:38PM
Aug-08-23 05:30PM
04:26PM
04:01PM Loading…
04:01PM
Aug-01-23 04:15PM
Jul-20-23 08:05AM
Jul-19-23 07:08AM
Jul-17-23 08:05AM
Jun-29-23 08:05AM
Jun-28-23 09:20AM
Jun-14-23 08:16AM
May-22-23 08:05AM
May-18-23 07:04AM
May-16-23 08:00AM
May-02-23 04:30PM
06:03AM
Apr-26-23 05:28PM
Apr-25-23 02:39PM
Apr-21-23 04:58AM
Apr-19-23 04:15PM
Apr-17-23 07:38AM
Apr-16-23 06:30AM
Mar-23-23 06:09AM
Mar-21-23 09:35AM
Mar-20-23 12:25PM
Mar-10-23 09:35AM
Feb-25-23 08:26AM
Feb-23-23 05:36PM
11:57AM
Feb-22-23 05:25PM
04:01PM
03:01PM
09:35AM
Feb-21-23 09:01AM
Feb-16-23 10:01AM
Feb-13-23 09:55AM
Feb-10-23 11:01AM
Jan-30-23 07:10PM
Dec-06-22 06:02AM
Nov-09-22 05:31AM
Nov-03-22 05:55PM
04:01PM
Oct-27-22 04:15PM
Oct-14-22 09:49AM
Oct-12-22 08:55AM
03:01AM
Sep-23-22 12:02PM
Sep-18-22 09:11AM
Aug-30-22 08:50AM
06:00AM
Aug-29-22 09:55AM
Aug-12-22 09:55AM
Aug-04-22 05:45PM
04:01PM
Jul-28-22 04:15PM
Jul-21-22 08:05AM
Jul-18-22 09:21AM
Jun-07-22 08:55AM
Jun-01-22 04:30PM
May-08-22 08:09AM
May-05-22 05:45PM
04:01PM
May-04-22 06:35PM
May-02-22 04:30PM
Apr-28-22 04:15PM
Apr-21-22 04:30PM
Apr-11-22 08:59AM
Mar-30-22 06:40AM
Mar-29-22 08:05AM
Feb-28-22 05:00PM
Feb-24-22 06:20PM
04:01PM
Feb-17-22 04:30PM
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIOGEN INC.10% OwnerSep 26 '23Sale0.506,000,0003,000,00017,652,466Sep 28 05:30 PM